Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

QLGN

Qualigen Therapeutics (QLGN)

Qualigen Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:QLGN
DateTimeSourceHeadlineSymbolCompany
21/09/202406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
20/09/202423:00GlobeNewswire Inc.Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings PanelNASDAQ:QLGNQualigen Therapeutics Inc
10/09/202407:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
07/09/202407:00GlobeNewswire Inc.Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)NASDAQ:QLGNQualigen Therapeutics Inc
07/09/202406:30GlobeNewswire Inc.Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public OfferingNASDAQ:QLGNQualigen Therapeutics Inc
07/09/202405:46Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:QLGNQualigen Therapeutics Inc
05/09/202423:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
05/09/202423:00GlobeNewswire Inc.Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public OfferingNASDAQ:QLGNQualigen Therapeutics Inc
05/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QLGNQualigen Therapeutics Inc
23/08/202406:41Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
15/08/202406:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QLGNQualigen Therapeutics Inc
10/08/202406:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QLGNQualigen Therapeutics Inc
10/08/202405:58Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
09/08/202420:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QLGNQualigen Therapeutics Inc
08/08/202407:28Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
06/08/202406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
26/07/202401:57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QLGNQualigen Therapeutics Inc
19/07/202407:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
16/07/202407:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
15/07/202420:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
12/07/202407:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
01/07/202422:00GlobeNewswire Inc.Lifecore Biomedical Announces Cooperation Agreement with 22NWNASDAQ:QLGNQualigen Therapeutics Inc
31/05/202406:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
31/05/202406:00GlobeNewswire Inc.Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting DeterminationNASDAQ:QLGNQualigen Therapeutics Inc
15/05/202406:05Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:QLGNQualigen Therapeutics Inc
04/05/202410:59Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
16/04/202421:00GlobeNewswire Inc.Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™NASDAQ:QLGNQualigen Therapeutics Inc
10/04/202422:00GlobeNewswire Inc.Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
09/04/202422:00GlobeNewswire Inc.Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
27/02/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QLGN